{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.7","upperLimit":"43.8","value":"32.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"description":"ITP remission was defined as maintaining every platelet count ≥ 50 x 10\\^9/L for at least 6 months in the absence of romiplostim and any other therapies to treat ITP.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg to reach a target platelet count of ≥ 50 x 10\\^9/L. At the completion of the 12-month treatment period, participants receiving only romiplostim and with a platelet count ≥ 50 x 10\\^9/L entered the tapering period, during which the romiplostim dose was decreased by 1 µg/kg every 2 weeks, for up to 19 weeks. Participants who had tapered off treatment with romiplostim and whose platelet count dropped below 50 x 10\\^9/L could reinitiate romiplostim for up to 8 weeks.","id":"OG000","title":"Romiplostim"}],"paramType":"NUMBER","populationDescription":"Safety analysis set","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Percentage of Participants With ITP Remission","type":"SECONDARY","unitOfMeasure":"percentage of participants"}